UPDATE: Exact Sciences' Q1 Revenues Drop 23 Percent

As the firm moves toward clinical trials for its Cologuard colorectal cancer test, almost all of Exact Sciences' revenues were from licensing deals, while product revenues dropped to $4,000 from $12,000 a year ago.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.